Dynavax Technologies Corporation (DVAX)
USD 11.44
(1.69%)
USD 11.44
(1.69%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 232.28 Million USD | -67.86% |
| 2022 | 722.68 Million USD | 64.45% |
| 2021 | 439.44 Million USD | 844.0% |
| 2020 | 46.55 Million USD | 32.18% |
| 2019 | 35.21 Million USD | 329.6% |
| 2018 | 8.19 Million USD | 2407.03% |
| 2017 | 327 Thousand USD | -97.04% |
| 2016 | 11.04 Million USD | 172.67% |
| 2015 | 4.05 Million USD | -63.29% |
| 2014 | 11.03 Million USD | -1.95% |
| 2013 | 11.25 Million USD | 15.82% |
| 2012 | 9.71 Million USD | -55.06% |
| 2011 | 21.61 Million USD | -9.75% |
| 2010 | 23.95 Million USD | -40.6% |
| 2009 | 40.31 Million USD | 8.69% |
| 2008 | 37.09 Million USD | 163.21% |
| 2007 | 14.09 Million USD | 190.76% |
| 2006 | 4.84 Million USD | -66.93% |
| 2005 | 14.65 Million USD | -1.06% |
| 2004 | 14.81 Million USD | 1693.22% |
| 2003 | 826 Thousand USD | -42.12% |
| 2002 | 1.42 Million USD | -39.51% |
| 2001 | 2.35 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 73.79 Million USD | 45.29% |
| 2024 Q1 | 50.79 Million USD | -8.64% |
| 2023 Q2 | 60.24 Million USD | 28.39% |
| 2023 Q1 | 46.92 Million USD | -74.57% |
| 2023 Q4 | 55.59 Million USD | -20.02% |
| 2023 Q3 | 69.51 Million USD | 15.38% |
| 2023 FY | 232.28 Million USD | -67.86% |
| 2022 Q2 | 256.46 Million USD | 124.98% |
| 2022 FY | 722.68 Million USD | 64.45% |
| 2022 Q4 | 184.49 Million USD | 9.99% |
| 2022 Q3 | 167.73 Million USD | -34.6% |
| 2022 Q1 | 113.99 Million USD | -41.56% |
| 2021 Q3 | 108.27 Million USD | 105.19% |
| 2021 Q2 | 52.76 Million USD | -36.68% |
| 2021 Q4 | 195.07 Million USD | 80.17% |
| 2021 Q1 | 83.33 Million USD | 326.27% |
| 2021 FY | 439.44 Million USD | 844.0% |
| 2020 Q3 | 13.41 Million USD | 402.77% |
| 2020 Q2 | 2.66 Million USD | -75.57% |
| 2020 FY | 46.55 Million USD | 32.18% |
| 2020 Q4 | 19.55 Million USD | 45.74% |
| 2020 Q1 | 10.91 Million USD | 3.3% |
| 2019 FY | 35.21 Million USD | 329.6% |
| 2019 Q1 | 5.77 Million USD | 8.56% |
| 2019 Q2 | 8.3 Million USD | 43.79% |
| 2019 Q3 | 10.57 Million USD | 27.39% |
| 2019 Q4 | 10.57 Million USD | -0.05% |
| 2018 Q3 | 1.46 Million USD | 16.51% |
| 2018 FY | 8.19 Million USD | 2407.03% |
| 2018 Q1 | 165 Thousand USD | 685.71% |
| 2018 Q2 | 1.25 Million USD | 660.0% |
| 2018 Q4 | 5.31 Million USD | 264.0% |
| 2017 Q2 | 105 Thousand USD | -29.05% |
| 2017 FY | 327 Thousand USD | -97.04% |
| 2017 Q4 | 21 Thousand USD | -60.38% |
| 2017 Q3 | 53 Thousand USD | -49.52% |
| 2017 Q1 | 148 Thousand USD | -97.97% |
| 2016 Q1 | 942 Thousand USD | 37.52% |
| 2016 Q2 | 2.64 Million USD | 181.0% |
| 2016 Q4 | 7.29 Million USD | 4401.23% |
| 2016 Q3 | 162 Thousand USD | -93.88% |
| 2016 FY | 11.04 Million USD | 172.67% |
| 2015 Q1 | 627 Thousand USD | -72.46% |
| 2015 Q2 | 1.55 Million USD | 147.21% |
| 2015 Q4 | 685 Thousand USD | -42.34% |
| 2015 Q3 | 1.18 Million USD | -23.35% |
| 2015 FY | 4.05 Million USD | -63.29% |
| 2014 FY | 11.03 Million USD | -1.95% |
| 2014 Q4 | 2.27 Million USD | 3.08% |
| 2014 Q1 | 3.49 Million USD | 22.87% |
| 2014 Q2 | 3.04 Million USD | -12.86% |
| 2014 Q3 | 2.2 Million USD | -27.53% |
| 2013 Q3 | 2.92 Million USD | -13.71% |
| 2013 Q4 | 2.84 Million USD | -2.73% |
| 2013 Q1 | 2.08 Million USD | 15.45% |
| 2013 FY | 11.25 Million USD | 15.82% |
| 2013 Q2 | 3.39 Million USD | 62.69% |
| 2012 Q3 | 2.87 Million USD | 7.08% |
| 2012 Q2 | 2.68 Million USD | 14.21% |
| 2012 Q1 | 2.35 Million USD | -79.43% |
| 2012 FY | 9.71 Million USD | -55.06% |
| 2012 Q4 | 1.8 Million USD | -37.16% |
| 2011 FY | 21.61 Million USD | -9.75% |
| 2011 Q4 | 11.42 Million USD | 873.34% |
| 2011 Q1 | 1.74 Million USD | -1.25% |
| 2011 Q2 | 7.26 Million USD | 316.8% |
| 2011 Q3 | 1.17 Million USD | -83.85% |
| 2010 Q3 | 11.64 Million USD | 431.68% |
| 2010 Q1 | 8.34 Million USD | 281.18% |
| 2010 Q2 | 2.19 Million USD | -73.74% |
| 2010 FY | 23.95 Million USD | -40.6% |
| 2010 Q4 | 1.76 Million USD | -84.84% |
| 2009 Q4 | 2.18 Million USD | -24.54% |
| 2009 FY | 40.31 Million USD | 8.69% |
| 2009 Q3 | 2.9 Million USD | -81.74% |
| 2009 Q2 | 15.88 Million USD | -17.89% |
| 2009 Q1 | 19.34 Million USD | 61.94% |
| 2008 Q2 | 9.97 Million USD | 58.03% |
| 2008 Q1 | 6.31 Million USD | -32.07% |
| 2008 FY | 37.09 Million USD | 163.21% |
| 2008 Q4 | 11.94 Million USD | 34.87% |
| 2008 Q3 | 8.85 Million USD | -11.23% |
| 2007 Q4 | 9.29 Million USD | 816.67% |
| 2007 Q3 | 1.01 Million USD | -43.67% |
| 2007 Q2 | 1.8 Million USD | -9.27% |
| 2007 Q1 | 1.98 Million USD | -18.62% |
| 2007 FY | 14.09 Million USD | 190.76% |
| 2006 Q1 | 288 Thousand USD | -52.0% |
| 2006 Q2 | 529 Thousand USD | 83.68% |
| 2006 FY | 4.84 Million USD | -66.93% |
| 2006 Q3 | 1.59 Million USD | 200.95% |
| 2006 Q4 | 2.43 Million USD | 53.14% |
| 2005 Q3 | 404 Thousand USD | -57.61% |
| 2005 Q4 | 600 Thousand USD | 48.51% |
| 2005 FY | 14.65 Million USD | -1.06% |
| 2005 Q1 | 12.69 Million USD | 417.23% |
| 2005 Q2 | 953 Thousand USD | -92.49% |
| 2004 Q3 | 3.66 Million USD | -33.36% |
| 2004 Q4 | 2.45 Million USD | -32.92% |
| 2004 Q1 | 3.2 Million USD | 353.32% |
| 2004 FY | 14.81 Million USD | 1693.22% |
| 2004 Q2 | 5.49 Million USD | 71.36% |
| 2003 FY | 826 Thousand USD | -42.12% |
| 2003 Q2 | 96 Thousand USD | 0.0% |
| 2003 Q3 | 23 Thousand USD | -76.04% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q4 | 707 Thousand USD | 2973.91% |
| 2002 FY | 1.42 Million USD | -39.51% |
| 2001 FY | 2.35 Million USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 59.016% |
| Embecta Corp. | 1.12 Billion USD | 79.275% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 52.285% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -99.67% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 65.586% |
| PainReform Ltd. | - USD | -Infinity% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -359.214% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -864.123% |
| SCYNEXIS, Inc. | 140.14 Million USD | -65.75% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -11944.82% |
| Cosmos Health Inc. | 53.37 Million USD | -335.177% |
| Journey Medical Corporation | 79.18 Million USD | -193.358% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -864.123% |
| Safety Shot Inc | 202.67 Thousand USD | -114511.931% |
| Alpha Teknova, Inc. | 36.68 Million USD | -533.202% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 49.979% |
| Bright Green Corporation | 401.49 Thousand USD | -57755.344% |
| Procaps Group, S.A. | 409.92 Million USD | 43.334% |
| Theratechnologies Inc. | 81.76 Million USD | -184.091% |
| Harrow Health, Inc. | 130.19 Million USD | -78.415% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -1723.981% |
| Biofrontera Inc. | 34.07 Million USD | -581.765% |
| DURECT Corporation | 8.54 Million USD | -2617.408% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 61.765% |
| Cronos Group Inc. | 88.84 Million USD | -161.461% |
| OptiNose, Inc. | 70.98 Million USD | -227.22% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 47.534% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -3466.372% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 46.372% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -1796.42% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -487.28% |
| Radius Health, Inc. | 2.88 Billion USD | 91.941% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -618.951% |
| ProPhase Labs, Inc. | 44.38 Million USD | -423.351% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 77.175% |
| Procaps Group S.A. | 409.92 Million USD | 43.334% |
| Alvotech | 91.43 Million USD | -154.046% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -17740.553% |
| Viatris Inc. | 15.42 Billion USD | 98.494% |
| Rockwell Medical, Inc. | 83.61 Million USD | -177.812% |
| Aytu BioPharma, Inc. | 81 Million USD | -186.763% |
| SIGA Technologies, Inc. | 139.91 Million USD | -66.015% |
| Tilray Brands, Inc. | 788.94 Million USD | 70.558% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -81.103% |
| Shineco, Inc. | 9.8 Million USD | -2269.796% |
| PetIQ, Inc. | 1.1 Billion USD | 78.921% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -1935600.0% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 87.691% |
| Alimera Sciences, Inc. | 80.75 Million USD | -187.644% |
| Silver Spike Investment Corp. | 11.72 Million USD | -1881.585% |
| Assertio Holdings, Inc. | 152.06 Million USD | -52.749% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -3889.497% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -1233.663% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -21479.61% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -730.683% |
| Hempacco Co., Inc. | 4.04 Million USD | -5641.593% |
| Talphera, Inc. | 651 Thousand USD | -35581.106% |
| Alvotech | 91.43 Million USD | -154.046% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 26.634% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 82.083% |
| Currenc Group, Inc. | 53.25 Million USD | -336.17% |
| Kamada Ltd. | 144.75 Million USD | -60.463% |
| Indivior PLC | 1.09 Billion USD | 78.748% |
| Evoke Pharma, Inc. | 5.18 Million USD | -4383.702% |
| Flora Growth Corp. | 76.07 Million USD | -205.352% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -21479.61% |
| Evolus, Inc. | 202.08 Million USD | -14.944% |
| HUTCHMED (China) Limited | 837.99 Million USD | 72.281% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 63.953% |
| Akanda Corp. | 2.16 Million USD | -10653.63% |